| |
 |
Russell Dean Stucky Patents |
|
Inventor: Stucky; Russell Dean
Address: Indianapolis, IN
No. of patents: 6
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| 7399774 |
6-substituted nicotinamide derivatives as opioid receptor antagonists |
July 15, 2008 |
| A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein. ##S |
| 7381719 |
Diaryl ethers as opioid receptor antagonist |
June 3, 2008 |
| A compound of the formula (I) wherein the variables X.sub.1 to X.sub.10, R.sup.1 to R.sup.7 including R.sup.3', E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prev |
| 6730792 |
.beta.3 adrenergic agonists |
May 4, 2004 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can a |
| 6541497 |
Hypoglycemic and hypolipidemic compounds |
April 1, 2003 |
| This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia. |
| 6353027 |
Hypoglycemic and hypolipidemic compounds |
March 5, 2002 |
| This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia. |
| 6194446 |
Hypoglycemic and hypolipidemic compounds |
February 27, 2001 |
| This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia. |
|
|
|
